Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Total Current Liabilities (2016 - 2025)

Sunshine Biopharma (SBFM) has disclosed Total Current Liabilities for 11 consecutive years, with $6.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Current Liabilities rose 46.88% year-over-year to $6.7 million, compared with a TTM value of $6.7 million through Sep 2025, up 46.88%, and an annual FY2024 reading of $6.3 million, up 13.74% over the prior year.
  • Total Current Liabilities was $6.7 million for Q3 2025 at Sunshine Biopharma, up from $5.6 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $6.9 million in Q4 2022 and bottomed at $91229.0 in Q4 2021.
  • Average Total Current Liabilities over 5 years is $3.8 million, with a median of $5.1 million recorded in 2023.
  • The sharpest move saw Total Current Liabilities crashed 91.32% in 2021, then soared 7497.38% in 2022.
  • Year by year, Total Current Liabilities stood at $91229.0 in 2021, then skyrocketed by 7497.38% to $6.9 million in 2022, then dropped by 19.9% to $5.6 million in 2023, then rose by 13.74% to $6.3 million in 2024, then rose by 5.33% to $6.7 million in 2025.
  • Business Quant data shows Total Current Liabilities for SBFM at $6.7 million in Q3 2025, $5.6 million in Q2 2025, and $5.8 million in Q1 2025.